Next-generation phenotypic antimicrobial susceptibility test platform: rapid resultsand comprehensive menus

此CRP SBIR提案的目标是为四个项目提供资金，以推进商业 Selux的快速、全面、低成本、表型抗生素敏感性的准备情况 测试(AST)系统。Selux的下一代表型(NGP)平台独特地实现了快速 AST提供全面的抗菌菜单，包括50种药物，来自分离株和 血培养阳性样本。目标1和目标2侧重于早期重要的成本降低项目 客户采用。目标1包括分析研究，以支持多个口腔小组和目标 2是DFM对Analyzer消耗品包的重新设计。目标3和目标4侧重于工作 对于以后的客户采用来说是必要的。目标3是一项为期一年的基准研究，将 将Selux NGP性能与传统AST系统和参考方法进行比较。通过 跨旧式系统改进系统工作流和基准测试AST性能 资金将有助于将Selux NGP定位为未来占主导地位的AST平台。

The goal of this CRP SBIR proposal is to fund four projects to advance the commercial readiness of Selux’s rapid, comprehensive, low-cost, phenotypic antibiotic susceptibility test (AST) system. Selux’s next-generation phenotyping (NGP) platform uniquely enables rapid AST with comprehensive antimicrobial menus of >50 drugs at a low cost from isolates and positive blood culture samples. Aims 1 and 2 focus on cost reduction projects important for early customer adoption. Aim 1 comprises analytical studies to support multiplex oral panels and Aim 2 is a DFM redesign of the Analyzer consumable pack. Aims 3 and 4 focuses on work necessary for later customer adoption. Aim 3 is a yearlong benchmarking study that will compare Selux NGP performance against legacy AST systems and reference methods. By improving system workflows and benchmarking AST performance across legacy systems CRP funding will help position Selux NGP as the dominant AST platform of the future.